I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
A randomized study to evaluate the safety and efficacy of t..:
M. S. Brose
;
Yu. Panaseykin
;
B. Konda
...
https://ogsh.abvpress.ru/jour/article/view/740/518. , 2022
Link:
https://ogsh.abvpress.ru/jour/article/view/740
RT Journal T1
A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer ; Рандомизированное исследование по оценке безопасности и эффективности двух дозировок ленватиниба – 18 и 24 мг – у пациентов с радиойодр...
UL https://suche.suub.uni-bremen.de/peid=base-ftjogsh:oai:oai.ogsh.elpub.ru:article_740&Exemplar=1&LAN=DE A1 M. S. Brose A1 Yu. Panaseykin A1 B. Konda A1 C. de la Fouchardiere A1 B. G.M. Hughes A1 A. G. Gianoukakis A1 Y. J. Park A1 I. Romanov A1 M. K. Krzyzanowska A1 S. Leboulleux A1 T. A. Binder A1 C. Dutcus A1 R. Xie A1 M. H. Taylor PB ABV-press" Publishing House", LLC. YR 2022 K1 стартовая доза K1 радиойодрефрактерный дифференцированный рак щитовидной железы K1 ингибитор тирозинкиназ JF https://ogsh.abvpress.ru/jour/article/view/740/518 LK http://dx.doi.org/https://ogsh.abvpress.ru/jour/article/view/740 DO https://ogsh.abvpress.ru/jour/article/view/740 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)